Kohjin Bio Co., Ltd. (TYO:177A)
599.00
-16.00 (-2.60%)
Nov 18, 2026, 10:48 AM JST
Kohjin Bio Revenue
Kohjin Bio had revenue of 973.00M JPY in the quarter ending September 30, 2026, a decrease of -24.28%. This brings the company's total for the last twelve months to 4.38B, down -15.78% year-over-year. In the fiscal year ending March 31, 2026, Kohjin Bio had annual revenue of 4.94B, down -5.13%. That makes Kohjin Bio the 31,963rd largest company in the world by revenue and 3,355th in Japan.
Revenue (ttm)
4.38B
Revenue Growth
-15.78%
P/S Ratio
0.72
Revenue / Employee
24.90M
Employees
176
Market Cap
3.06B
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full Kohjin Bio breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.94B | -267.00M | -5.13% |
| Mar 31, 2025 | 5.21B | 436.00M | 9.14% |
| Mar 31, 2024 | 4.77B | 28.00M | 0.59% |
| Mar 31, 2023 | 4.74B | 795.00M | 20.14% |
| Mar 31, 2022 | 3.95B | 809.83M | 25.81% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 14.02B |
| Human Metabolome Technologies | 1.48B |
| MEDINET | 998.00M |
| SUSMED,Inc. | 679.00M |
| PRISM BioLab Co.,LTD | 518.00M |
| Kringle Pharma | 442.00M |
| D. Western Therapeutics Institute | 140.90M |
| Ribomic | 19.00M |